Metabolic · 9 min read · Published September 8, 2026

Retatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide

One table with the headline weight-loss numbers, their trial names and their durations, so a 36-week Phase 2 result is never compared to an 80-week Phase 3 result by accident. Covers retatrutide, tirzepatide, semaglutide, CagriSema, MariTide, amycretin, eloralintide, enicepatide and the oral drugs.

Is retatrutide better than tirzepatide?

In its pivotal TRIUMPH-1 trial, retatrutide 12 mg produced 28.3 percent average weight loss over 80 weeks versus 2.2 percent for placebo, higher than tirzepatide's 20.9 percent in SURMOUNT-1. Retatrutide is not approved; submission is expected late 2026. Skin sensitivity (dysesthesia) was reported by 12.5 percent on the top dose, a side effect not seen with tirzepatide.

There is no head-to-head trial of retatrutide against tirzepatide, and there may never be one. What exists are separate trials with different lengths, doses and entry criteria. The table below is built to make that visible. For mechanism and citations, each name links to its profile; for the side-by-side data view, use the comparison pages.

The numbers, with their trials and durations

Does retatrutide burn fat or muscle?

Like all GLP-1-class drugs, retatrutide reduces both fat and lean mass, with fat making up most of the loss. Its glucagon activity raises energy expenditure and liver fat clearance, which is why triple agonists reach higher totals. Muscle-preserving add-ons are the answer the industry is building: apitegromab preserved 55 percent of lean mass on tirzepatide, and bimagrumab with semaglutide produced weight loss that was 93 percent fat.

Profiles: apitegromab, bimagrumab, trevogrumab, enobosarm.

Which GLP-1 can be taken orally?

Three approved options exist in the US as of September 2026: Rybelsus (oral semaglutide for diabetes), the Wegovy pill (oral semaglutide 25 mg for weight, December 2025) and Foundayo (orforglipron, April 2026), the first small-molecule GLP-1 pill with no food or water restrictions. Aleniglipron, elecoglipron and HRS-7535 are in Phase 3. Danuglipron was discontinued.

Oral peptides like semaglutide need an absorption enhancer and fasting conditions; small molecules like orforglipron do not, which is the practical difference. Efficacy so far favors the injectables by a wide margin. See the oral GLP-1 profiles.

What is stronger than retatrutide?

Nothing with Phase 3 data. Enicepatide's 22.5 percent at 48 weeks and eloralintide's 20.1 percent are Phase 2 numbers at shorter durations. Combination regimens (a GLP-1 drug plus a muscle-preserving antibody or an amylin) are where the field is heading, but no combination has reported more total weight loss than retatrutide alone.

Side effects worth knowing in 2026

• Gastrointestinal effects (nausea, vomiting, constipation) are class-wide and dose-related for every GLP-1 drug.
• Dysesthesia (tingling, altered skin sensation) appeared in 12.5 percent of participants on 12 mg retatrutide in TRIUMPH-1 (20.9 percent in TRIUMPH-4) and about 23 percent on Wegovy HD 7.2 mg versus about 6 percent on placebo. Its mechanism is not established.
• Lean-mass loss is universal to the class and is the reason muscle-preserving combinations are in trials.
• Orforglipron's label carries a boxed warning for thyroid C-cell tumors, as do the injectable GLP-1 drugs.

For the amount-to-units arithmetic on any of the injectables, the calculator handles mg and mcg and shows the mark on your syringe; the half-life reference explains why some are weekly and one is monthly.